DCRI Statistician Advocates for Open Science During COVID-19
A recent letter to the editor provided recommendations for encouraging open science in COVID-19 clinical trials, such as incentives for data sharing during the project funding stage.
New Study Analyzes Secondary COVID-19 Transmission for In-Person Schooling
The rate of transmission within schools was found to be much lower than the rate of community spread of the disease.
Global Digital Health Expert, Eric Perakslis, PhD, to Join Duke Clinical Research Institute as Chief Science & Digital Officer
Perakslis will provide strategic vision and oversight of DCRI’s digital research initiatives and technology affairs to advance the academic institute’s clinical research portfolio.
DCRI, Verily, and HERO Registry to Support Long-Term Safety Study of COVID-19 Vaccine
The Duke Clinical Research Institute (DCRI) and Verily are utilizing the HERO Registry and community to launch a study to gain long-term insights about the COVID-19 vaccine developed by Pfizer and BioNTech, including real-world safety data. This study, which is funded by Pfizer, will follow vaccinated healthcare workers for two years to assess their experiences after receiving the vaccine.
Novel Blueprint Leverages Behavioral Economics to Inform Clinical Practice
DCRI researchers have created a blueprint to automatically update clinicians on their prescribing habits and those of their peers.
Survey Designed by DCRI Gains Insight into COVID-19 Preferences
DCRI population health scientists conducted a discrete choice experiment to improve understanding of how people weigh risks associated with COVID-19.
DCRI Faculty Members Recognized as ‘Pioneers’
The annual list, which examined papers published over the last decade, honors researchers who were in the top 1 percent of citations in their fields.
AHA 2020: AHA COVID Registry Sheds Light on Pandemic’s Impact on Racial Minorities
Two presentations on the American Heart Association COVID Registry shared data about COVID-19 hospitalizations collected from over 100 hospitals.
DCRI’s CEC Group Contributes to AHA Late-Breakers
Through new ways of working and collaborations across Duke, the DCRI’s Clinical Events Classification group is continuously improving on its processes.
AHA 2020: RIVER Shows Rivaroxaban Safe for Patients with Bioprosthetic Valves
The study, which is the only randomized trial testing rixaroxaban in this patient population, builds on previous evidence established by the DCRI-led ROCKET-AF and ARISTOTLE studies.